Course overview

Cognitive Decline and Brain Health

In this course, you will explore the current standard of care in Alzheimer's disease and the standard of care clinicians should strive to achieve with patients. Specific goals for treatment and strategies used to reverse and sustain cognitive decline are addressed.

Dale Bredesen, MD

 Conference Series

AIHM 2020 Annual Conference

 Required Lessons


 Time to Complete

1 hour

 non-CME Eligible*

CME Expired

What you will learn

  • Course Summary

  • This course will explore the theme of the 2020 conference in the following ways: PEOPLE: Beyond the millions affected by dementia, and its rising impact, cognition for most is suboptimal. PLANET: The neurodegenerative process represents a global problem, reducing resources, affecting millions of families, requiring nursing homes and caretaker time, and causing disease in the caretakers themselves. PURPOSE: To reduce the global burden of neurodegenerative disease by identifying the contributors, specific for each disease and each individual, addressing these contributors, and creating global prevention and therapeutic programs.
    By the end of this course, learners will be able to:
    • Differentiate the current standard of care versus the 21st century standards of care for neurodegenerative diseases.
    • Describe strategies used to reverse and sustain cognitive decline in people with Alzheimer's disease.
    • Identify goals for treatment and prevention of Alzheimer's disease.
    • Recognize the specific reasons for failure of Alzheimer's patients to improve.

Course includes:

  • Video recording
  • Downloadable audio
  • Speaker handout(s)
  • 1 Quiz
  • 1 Evaluation
  • Certificate of Completion

Included in this course

Course Faculty

Dale Bredesen, MD

Faculty Disclosure: Consultant - AHNP (Apollo Health New Practices). All disclosures were mitigated prior to the activity.
About Dale
Dr. Bredesen earned his MD from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF), before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as founding President and CEO.

Dr. Bredesen’s research explores previously uncharted territory in explaining the physical mechanism behind the erosion of memory seen in Alzheimer’s disease, and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkable early results. Dr. Bredesen is a prodigious innovator in medicine, with over thirty patents to his name. Notably, he put much of his findings and research into the 2017 New York Times‘ Best-Seller, The End of Alzheimer’s.

*CME/CEU Credits

The CME for this course has expired, however you will continue to have access to your purchased content. 

Enroll Now!

This course is self-paced with no set beginning or end date. You may complete this course on your own schedule and pace. Enrolling in and purchasing this course grants you access to its contents in perpetuity. All required course activities must be completed to earn any eligible continuing education credit(s) and obtain a certificate of completion for this course. 
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine and/or the Academy of Integrative Health & Medicine.